The estimated Net Worth of Lauren Mastrocola is at least $1.82 Milione dollars as of 16 June 2022. Lauren Mastrocola owns over 3,000 units of Praxis Precision Medicines stock worth over $1,818,795 and over the last 4 years he sold PRAX stock worth over $0.
Lauren has made over 2 trades of the Praxis Precision Medicines stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of PRAX stock worth $5,790 on 16 June 2022.
The largest trade he's ever made was exercising 12,218 units of Praxis Precision Medicines stock on 2 November 2020 worth over $40,319. On average, Lauren trades about 1,015 units every 39 days since 2020. As of 16 June 2022 he still owns at least 31,391 units of Praxis Precision Medicines stock.
You can see the complete history of Lauren Mastrocola stock trades at the bottom of the page.
Lauren Mastrocola is the VP of Fin. & Principal Accounting Officer at Praxis Precision Medicines.
Lauren's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Over the last 4 years, insiders at Praxis Precision Medicines have traded over $16,246,895 worth of Praxis Precision Medicines stock and bought 242,294 units worth $603,092 . The most active insiders traders include Holdings A/S Novo, Parallel Master Fund L.P.Bl... e Dean J Mitchell. On average, Praxis Precision Medicines executives and independent directors trade stock every 48 days with the average trade being worth of $3,178,530. The most recent stock trade was executed by Jill De Simone on 5 October 2023, trading 14,500 units of PRAX stock currently worth $25,375.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Praxis Precision Medicines executives and other stock owners filed with the SEC include: